PDS novel methods will accurately and simultaneously address, without the use of probes, the mechanism of aggregation, the extent of aggregation, and the stability of the protein product under varying formulation conditions. Evaluation of excipients in the stability of the protein therapeutic. This evaluation is essential to developability assessment of biologics and biosimilars.

Pre-formulation is critical to lowering the risk of product recalls.